J Clin Neurol.  2017 Apr;13(2):181-186. 10.3988/jcn.2017.13.2.181.

Association of Helicobacter pylori with Parkinson's Disease

Affiliations
  • 1Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India. rukminimridula@gmail.com
  • 2Department of Neurology, Nizamabad Neuro Super Specialty Hospital, Nizamabad, India.
  • 3Department of Clinical Research & Neurology, Yashoda Hospitals, Hyderabad, India.

Abstract

BACKGROUND AND PURPOSE
Parkinson's disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients.
METHODS
We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean "˜off' Unified Parkinson's Disease Rating Scale (UPDRS)-III score, mean "˜on' UPDRS-III score, mean onset time, mean "˜on' duration, and mean daily "˜on' time were measured at baseline and at a 3-week follow-up.
RESULTS
H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer "˜on' duration and daily "˜on' time, and better "˜on' UPDRS-III scores. Seropositive patients took a significantly longer time to turn "˜on' after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean "˜on' UPDRS-III score, onset time, "˜on' duration, and daily "˜on' time.
CONCLUSIONS
H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes.

Keyword

Parkinson's disease; H. pylori infection; prevalence; triple therapy; Indian patients

MeSH Terms

Follow-Up Studies
Helicobacter pylori*
Helicobacter*
Humans
Levodopa
Male
Nervous System Diseases
Outcome Assessment (Health Care)
Parkinson Disease*
Prevalence
Prospective Studies
Levodopa

Reference

1. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol. 2012; 19:864–869. PMID: 22248366.
Article
2. Gupta BM, Bala A. Parkinson's disease in India: an analysis of publications output during 2002-2011. Int J Nutr Pharmacol Neurol Dis. 2013; 3:254–262.
Article
3. Gourie-Devi M. Epidemiology of neurological disorders in India: review of background, prevalence and incidence of epilepsy, stroke, Parkinson's disease and tremors. Neurol India. 2014; 62:588–598. PMID: 25591669.
Article
4. Wu YH, Liao YC, Chen YH, Chang MH, Lin CH. Risk of premotor symptoms in patients with newly diagnosed PD: a nationwide, population-based, case-control study in Taiwan. PLoS One. 2015; 10:e0130282. PMID: 26107935.
Article
5. Nafisah W, Najman A, Hamizah R, Azmin S, Rabani R. High prevalence of Helicobacter pylori infection in Malaysian Parkinson's disease patients. J Parkinsonism Restless Legs Syndr. 2013; 3:63–67.
6. Goodwin CS, Armstrong JA, Chilvers T, Peters M, Collins MD, Sly L, et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively. Int J Syst Evol Microbiol. 1989; 39:397–405.
Article
7. Johnson A, Kratz B, Scanlon L, Spivak A. Guts & glory H. pylori: cause of peptic ulcer. Eukaryon. 2007; 3:67–74.
8. Nisha KJ, Nandakumar K, Shenoy KT, Janam P. Periodontal disease and Helicobacter pylori infection: a community-based study using serology and rapid urease test. J Investig Clin Dent. 2016; 7:37–45.
Article
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55:181–184. PMID: 1564476.
Article
10. Aggarwal OP, Bhasin SK, Sharma AK, Chhabra P, Aggarwal K, Rajoura OP. A new instrument (scale) for measuring the socioeconomic status of a family: preliminary study. Indian J Community Med. 2005; 30:111–114.
11. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004; 19:1020–1028. PMID: 15372591.
12. Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. CNS Neurosci Ther. 2012; 18:380–387. PMID: 22070400.
Article
13. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter. 2005; 10:267–275. PMID: 16104942.
Article
14. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, et al. Differential effect of Helicobacter pylori eradication on timetrends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter. 2010; 15:279–294. PMID: 20633189.
Article
15. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006; 66:1824–1829. PMID: 16801644.
Article
16. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord. 2008; 23:1696–1700. PMID: 18649391.
17. Choudhuri G, Mohindra S. Epidemiology of Helicobacter pylori in India. Indian J Gastroenterol. 2000; 19(Suppl 1):S3–S6. PMID: 11060968.
18. Blaecher C, Smet A, Flahou B, Pasmans F, Ducatelle R, Taylor D, et al. Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Pharmacol Ther. 2013; 38:1347–1353. PMID: 24117797.
19. Bu XL, Wang X, Xiang Y, Shen LL, Wang QH, Liu YH, et al. The association between infectious burden and Parkinson's disease: a case-control study. Parkinsonism Relat Disord. 2015; 21:877–881. PMID: 26037459.
20. Schulz JD, Hawkes E, Shaw CA. Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomenator. Med Hypotheses. 2006; 66:1222–1226. PMID: 16488551.
Article
21. Soykan I, Lin Z, Bennett JP, McCallum RW. Gastric myoelectrical activity in patients with Parkinson's disease: evidence of a primary gastric abnormality. Dig Dis Sci. 1999; 44:927–931. PMID: 10235599.
22. Freestone PP, Lyte M. Microbial endocrinology: experimental design issues in the study of interkingdom signalling in infectious disease. Adv Appl Microbiol. 2008; 64:75–105. PMID: 18485281.
23. Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PLoS One. 2014; 9:e112330. PMID: 25411976.
Article
24. Bjarnason IT, Charlett A, Dobbs RJ, Dobbs SM, Ibrahim MA, Kerwin RW, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study. Helicobacter. 2005; 10:276–287. PMID: 16104943.
Article
25. Weller C, Oxlade N, Dobbs SM, Dobbs RJ, Charlett A, Bjarnason IT. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol Med Microbiol. 2005; 44:129–135. PMID: 15866206.
Article
26. Gupta A, Reddy BV, Mishra SS. Infectious causation of Parkinsonism: a review. J Dent Med Sci. 2012; 3:1–3.
Article
27. Arismendi-Morillo G, Hernández I, Mengual E, Fuenmayor A, Romero G, Lizarzábal M. Comparison of three methods based on endoscopic gastric biopsies for diagnosis of Helicobacter pylori active infection in a clinical setting. Arq Gastroenterol. 2011; 48:190–194. PMID: 21952704.
Article
28. Mégraud F, Floch P, Labenz J, Lehours P. Diagnostic of Helicobacter pylori infection. Helicobacter. 2016; 21(Suppl 1):8–13. PMID: 27531532.
Article
29. Vagarali MA, Metgud SC, Bannur H, Karadesai SG, Nagmoti JM. Clinical significance of various diagnostic techniques and emerging antimicrobial resistance pattern of Helicobacter Pylori from gastric biopsy samples. Indian J Med Microbiol. 2015; 33:560–564. PMID: 26470964.
Article
30. Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016; 6:39–43. PMID: 27530837.
Article
31. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008; 23:690–699. PMID: 18228568.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr